Pedrinelli R, Tarazi R C
J Pharmacol Exp Ther. 1985 Jun;233(3):643-9.
Calcium entry blockade in vivo preferentially antagonizes systemic pressor responses to alpha-2 adrenergic agonists, whereas relatively sparing alpha-1 mediated vasoconstriction; however, in vitro studies have given results discordant from those obtained in vivo. Because of these discrepancies we have compared the effect of calcium entry blockade by nitrendipine on systemic and local (autoperfused hindquarters) pressor responses to selective adrenergic agonists: cirazoline for alpha-1 and B-HT 920 for alpha-2. Pithed, vagotomized, normotensive Sprague-Dawley rats were used. Confirming previous results, nitrendipine (3.0 and 30.0 micrograms/kg/min X 15 min) selectively antagonized the systemic pressor responses to B-HT 920 without affecting significant responses to the alpha-1 agonist. However, in the isolated, autoperfused hindquarters of pithed rats, these same doses of nitrendipine depressed by 36 and 45% the maximum vasoconstrictor response to cirazoline. Because no significant vasoconstrictor response to B-HT 920 could be demonstrated in this same preparation, we induced supersensitivity to the alpha-2 agonist by reserpine pretreatment (0.3 mg/kg X 3 days). Reserpine increased vascular responsiveness to B-HT 920, without modifying its selective alpha-2 agonistic properties, as assessed by the use of selective alpha-1 (prazosin, 0.5 mg/kg i.v.) and alpha-2 (rauwolscine, 0.5 mg/kg i.v.) antagonists and of phentolamine (5 mg/kg i.v.), a nonspecific alpha adrenergic antagonist. After pretreatment with reserpine, nitrendipine antagonized both the B-HT 920-mediated vasoconstriction (by an average of 40 and 57%, respectively) and the cirazoline alpha-1-mediated vasoconstriction.(ABSTRACT TRUNCATED AT 250 WORDS)
体内钙内流阻滞优先拮抗对α-2肾上腺素能激动剂的全身升压反应,而相对保留α-1介导的血管收缩;然而,体外研究结果与体内研究结果不一致。由于这些差异,我们比较了尼群地平钙内流阻滞对选择性肾上腺素能激动剂(α-1用可乐定,α-2用B-HT 920)的全身和局部(自身灌注后肢)升压反应的影响。使用了脊髓横断、迷走神经切断、血压正常的Sprague-Dawley大鼠。证实了先前的结果,尼群地平(3.0和30.0微克/千克/分钟×15分钟)选择性拮抗对B-HT 920的全身升压反应,而不影响对α-1激动剂的显著反应。然而,在脊髓横断大鼠的离体、自身灌注后肢中,相同剂量的尼群地平使对可乐定的最大血管收缩反应降低了36%和45%。由于在同一制备中未显示出对B-HT 920的显著血管收缩反应,我们通过利血平预处理(0.3毫克/千克×3天)诱导对α-2激动剂的超敏反应。利血平增加了血管对B-HT 920的反应性,而不改变其选择性α-2激动特性,这通过使用选择性α-1(哌唑嗪,0.5毫克/千克静脉注射)和α-2(育亨宾,0.5毫克/千克静脉注射)拮抗剂以及酚妥拉明(5毫克/千克静脉注射)(一种非特异性α肾上腺素能拮抗剂)来评估。用利血平预处理后,尼群地平拮抗B-HT 920介导的血管收缩(分别平均为40%和57%)以及可乐定α-1介导的血管收缩。(摘要截短于250字)